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The c-fes protooncogene encodes a nonreceptor tyrosine kinase (Fes) implicated in cytokine receptor signal transduction,
granulocyte survival, and myeloid differentiation. To study the role of c-fes during myelopoiesis, we generated embryonic
stem (ES) cells with a targeted disruption of the c-fes locus. Targeted mutagenesis deletes the C-terminal SH2 and tyrosine
kinase domains of c-fes (referred to as c-fesc/c). We demonstrate that the c-fesc/c allele results in a truncated Fes protein
that retains the N-terminal oligomerization domain, but lacks both the SH2 and the tyrosine kinase domain. In vitro
differentiation of c-fesc/c ES cells results in hyperproliferation of an early myeloid cell. Generation of c-fesc/c mutant
chimeric mice causes lethality by E13.5 with embryos exhibiting pleiotropic defects, the most striking being cardiovascular
abnormalities. These results establish that c-fes is an important regulator of myeloid cell proliferation and embryonic
development. © 2002 Elsevier Science (USA)INTRODUCTION
Fes is a 93-kDa nonreceptor protein tyrosine kinase
encoded by the c-fes protooncogene expressed predomi-
nantly in myeloid cells (Feldman et al., 1985; MacDonald et
al., 1985; Smithgall et al., 1988) and vascular endothelial
cells (Greer et al., 1994). The Fes protein contains
N-terminal coiled-coil motifs, a central SH2 domain, and
C-terminal catalytic domain. Fes is detected at high levels
in mature granulocytes and monocytes, and terminal differ-
entiation of myeloid cells is associated with increased c-fes
mRNA (Liebermann and Hoffman-Liebermann, 1989) and
Fes catalytic activity (Glazer et al., 1986; Smithgall et al.,
1988; Yu et al., 1988). This expression pattern suggests a
role for Fes in normal myeloid development and/or func-
tion. Additional experiments implicate Fes as essential for
myeloid cell survival and terminal differentiation. For ex-
ample, introduction of Fes into immature K562 leukemia
cells restores their ability to undergo myeloid differentia-
tion (Yu et al., 1989). Moreover, inhibition of c-fes expres-
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All rights reserved.sion in HL60 cells by antisense oligonucleotides blocks
granulocyte differentiation due to activation of apoptosis
(Ferrari et al., 1992; Manfredini et al., 1993).
Fes is associated with multiple hematopoietic cytokine
receptors, providing evidence that this kinase is a compo-
nent of myeloid signaling pathways. Of note, Fes is phos-
phorylated and catalytically activated in response to stimu-
lation by IL-3, GM-CSF, erythropoietin, and IL-4 (Hanazono
et al., 1993; Izuhara et al., 1994; Linnekin et al., 1995).
Furthermore, Fes appears to bind to the common -chain of
the IL-3 and GM-CSF receptors (Hanazono et al., 1993). Fes
has also been shown to form a complex with gp130, the
common signal-transducing component of the leukemia
inhibitory factor, oncostatin M, IL-6, and IL-11 receptors
(Matsuda et al., 1995). Taken together, these results suggest
involvement of Fes in signaling pathways emanating from
multiple cytokine receptors.
Putative cellular substrates for Fes have been proposed,
but association with the BCR (break point cluster region)
protein, Syk, Stat1, and Stat3 are compelling given that
such proteins regulate myeloid development. Fes associates
with BCR via its N-terminal coiled-coil region, and this
interaction activates Ras signaling pathways (Li and Smith-
gall, 1996). Fes may also function in Syk-mediated FCR-
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signaling, as the SH2 domain of Syk includes an ideal
predicted binding site for autophosphorylated Fes tyrosine
811 (Songyang et al., 1994). Finally, GM-CSF signaling leads
to Fes-dependent activation of Stat3, implicating Fes in
Jak-Stat pathways (Brizzi et al., 1996; Nelson et al., 1998;
Park et al., 1998).
Despite evidence that Fes plays a role in myeloid cell
signaling and differentiation, the precise function of Fes
during myeloid development was not clearly defined. We
previously reported a targeted disruption of c-fes producing
a null allele expressing no detectable Fes protein (c-fes/)
(Hackenmiller et al., 2000). c-fes/ mice exhibit homeosta-
sis defects in B cells, macrophages, and neutrophils, com-
promised innate immunity, and increased activation of
Stat3 and Stat5 in response to IL-6 and GM-CSF. These
results demonstrate that Fes regulates Stat activation dur-
ing cytokine-mediated signal transduction.
In addition to this mutation (c-fes/), we also generated
embryonic stem (ES) cells with a targeted disruption of c-fes
that deletes the C-terminal SH2 and tyrosine kinase do-
mains of Fes (referred to as c-fesc/c). We believe the
c-fesc/c allele generates a truncated protein that retains the
N-terminal oligomerization domain, but lacks both the
SH2 and the tyrosine kinase domains. c-fesc/c ES cells are
capable of differentiating into monocytes and erythrocytes
in vitro, and in vivo c-fesc/c mutant cells contribute to T
cell, B cell, and monocytic populations. However, in vitro
differentiation of c-fesc/c ES cells results in hyperprolifera-
tion of early myeloid cells. Generation of c-fesc/c mutant
chimeric mice demonstrates that disruption of c-fes activ-
ity in the developing embryo leads to pleiotropic defects,
the most striking being cardiovascular abnormalities and
embryonic lethality. These results suggest a critical role for
c-fes in the control of myeloid cell proliferation and proper
embryonic development.
MATERIALS AND METHODS
Generation and characterization of c-fesc/c ES cells. A
genomic library from strain 129 mice (Stratagene) was screened
with a partial cDNA for the mouse c-fes (Wilks and Kurban, 1988).
An 18-kb genomic clone encoding the entire c-fes genomic locus
and 4–5 kb of upstream sequence was isolated and characterized by
using restriction mapping and partial nucleotide sequencing (data
not shown). Sequenced exons were identical to the corresponding
region of the published cDNA (Wilks and Kurban, 1988). The
targeting construct was designed to delete the entire SH2 domain
and the ATP binding pocket within the tyrosine kinase domain.
This vector was generated by insertion of a 10-kb EagI–EagI
fragment containing the 5 end of the c-fes locus into the NotI site
of pPNT (Tybulewicz et al., 1991), followed by ligation of a 1.2-kb
BamHI–KpnI fragment containing the 3 end of the c-fes locus (see
Fig. 1A). The resulting construct was linearized by NotI digestion
and electroporated into RW ES cells (Bradley et al., 1984). Homolo-
gous recombinants selected by G418 (250 g/ml) and gancyclovir (1
M) were screened by Southern blotting for presence of a recom-
binant 4.3-kb SphI band, in addition to the endogenous 9.4-kb
fragment, using a radiolabeled 300-bp KpnI–KpnI fragment from the
c-fes gene.
To generate homozygous mutant cell lines, c-fes/c ES were
cultured in the presence of increasing concentrations of G418
(1.0–2.0 mg/ml) (Mortensen et al., 1992), and surviving colonies
were assayed for loss of the wild-type c-fes allele.
In vitro differentiation and colony forming (clonogenic) assays
of ES cells. RW, c-fes/c, and c-fesc/c ES cells were adapted from
mitomycin-C-treated MEF feeder cells to 0.1% porcine skin gelatin
(Sigma, St. Louis, MO)-coated tissue culture plates. After passaging
three to four times onto gelatinized plates, these cells were used for
in vitro differentiation. ES cells (6  103 to 1.5  104) were plated
on 35-mm bacterial petri in methylcellulose differentiation media
under the conditions described in Olson et al. (1995). The ES cells
were allowed to differentiate into embryoid bodies (EBs) in a
humidified 5% CO2 atmosphere at 37°C. When differentiated by
this method, wild-type EBs should produce primitive erythrocytes,
definitive erythrocytes, macrophages, neutrophils, and early
megakaryocytes. At day 11, EBs were picked and cells were
identified by cytospin preparations stained with May-Grunwald-
Giemsa. For colony forming assays, after approximately 6 days of in
vitro differentiation, cystic EBs were washed free of methylcellu-
lose with PBS and disaggregated with trypsin (Gibco-BRL) and
mechanical shearing, using a 21-gauge needle and syringe. Cells
were replated into a secondary methylcellulose medium identical
to that used for the initial in vitro differentiation and incubated
under the same conditions. The number of cells plated was equal to
the number of cells in 50 embryoid bodies derived from wild-type
ES cells. Hematopoietic colonies were scored after 6–7 days by
using morphological and cytochemical data.
Generation of c-fes/c and c-fesc/c C57BL/6 chimeric mice.
ES cells from three independently derived c-fes/c clones and three
independently derived c-fesc/c clones (one from each c-fes/c ES
cell line) were microinjected into C57BL/6 donor blastocytes,
which were subsequently implanted into CD1 pseudopregnant
females (Bradley et al., 1984). The age of the embryos was defined
based on the day of implantation being E2.5. Mouse embryos were
dissected from Metofane-anesthetized females. Embryos were dis-
sected into PBS and fixed overnight at 4°C in 4% paraformaldehyde
in PBS. After dehydration in increasing concentrations of ethanol
(50, 70, 95, and 100%), the embryos were transferred into xylene
and embedded in paraffin before sectioning at 5 mM. Histological
sections were stained with hematoxylin and eosin (H  E).
Flow cytometry analysis. Thymus and liver were processed
into single cell suspension. Cells were treated with ammonium-
chloride lysis buffer, then resuspended in PBS. Each sample con-
taining 0.5–1.0  106 cells was stained with fluorescein isothiocya-
nate (FITC)- or phycoerythrin (PE)-conjugated antibodies and
analyzed on a dual laser cell sorter (FACSCAN; Becton Dickinson).
Propidium iodide uptake and scatter-gating for size were used to
exclude dead cells from the analysis. Monoclonal antibodies (MAb)
anti-CD4, anti-B220, anti-CD11b, and anti-Ly9.1 were used accord-
ing to the instructions of the supplier (PharMingen, San Diego,
CA). Cells were incubated with appropriate antibodies at 1 l/ml in
PBS  1% BSA  0.1% azide as recommended by the manufac-
turer. Cells were washed twice with PBS  0.1% azide and
analyzed immediately in 1 l/ml of propidium iodide. ES cell- and
blastocyst-derived cells were distinguished by FACS using the LY
9.1 Mab, which recognized only the progeny of ES cells (Nakayama
et al., 1993).
RT-PCR analysis. Total cellular RNA was prepared from un-
differentiated ES cells by using Trizol (Gibco BRL) according to the
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instructions of the manufacturer. Total RNA was reverse tran-
scribed (RT) and amplified by PCR with reagents from Perkin-
Elmer (Norwalk, CT) under the same optimized conditions as
described in Olson et al. (1995). Products were run on a 1% agarose
gel, and visualized with ethidium bromide. Primers used for PCR
are listed: upstream of deletion (exons 8–10), 5-ATTGTCTGTTGT-
GCCCAGTCATAGC-3 (5-sequence); 5-CCGGAGAAGTGGCTT-
TTAAGGATCT-3 (3-sequence); Spanning deletion (exons 10–15),
5-GAAGGACACCCACACTGGAGATCGT-3 (5-sequence); 5-
TGCTTTCCAAGTATTCCATGCCAGC-3 (3-sequence); Spanning
deletion (exons 10–16), 5-GAAGGACACCCACACTGGAGATC-
GT-3 (5-sequence); 5-CTTGAACGAGCTCCATGACGATGTA-3
(3-sequence); Within deletion (exons 11–16), 5-ATGGCCACCCC-
CGACATTTCATCAT-3 (5-sequence); 5-CTTGAACGAGCTCC-
ATGACGATGTA-3 (3-sequence); Downstream of deletion (exons
16–18), 5-CGACTTTCTCACCTTCCTGCGGACA-3 (5-sequence);
5-TCCCGTGTCTGCTGATTGGTGAGGT-3 (3-sequence); HPRT
(Konecki et al., 1982), 5-CACAGGACTAGAACACCTGC-3 (5-se-
quence); 5-GCTGGTGAAAAGGACCTCT-3 (3-sequence).
Generation of stably transfected ES cell lines. The human
truncated (exons 1–10) cDNA was generated by PCR using the
following primers: 5-CCCGTCTAGAACAGCACTATGGGCTT-
CTCTTCCGAGCTG-3 (5-sequence); 5-CCCTCTAGATCATC-
ACGAGAACTTGGGGCGGAAGATTCC-3 (3-sequence).
FIG. 1. Targeted disruption of the c-fes locus. (A) Top diagram shows entire mouse c-fes locus with exons (boxes) and relevant restriction
sites indicated. The middle diagram shows the targeting construct. The targeting vector was designed to delete the SH2 domain and the
ATP binding site within the tyrosine kinase domain. The deletion is replaced with the positive selectable marker PGK-neo. To enrich for
homologous recombination events, the negative selectable marker HSV-tk was employed. The bottom diagram represents the correctly
disrupted c-fes locus. The position of the probe used for RFLP analysis is indicated. E, EagI; S, SphI; X, XbaI; K, KpnI; B, BamHI; SL, SalI;
and BG, BglII. (B) Southern blot analysis of genomic DNA from targeted ES cells. Wild-type (9.4 kb) and disrupted (4.3 kb) SphI fragments
are indicated. Lanes 2 and 3 show DNA from ES cells derived from the primary targeting event; lane 4 shows DNA from ES cells grown
in 1.5 mg/ml G418 to select for homozygous c-fesc/c. Genotypes are indicated.
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FIG. 2. c-fes is not essential for erythroid, myeloid, or lymphoid cell development. (A) Cytospin cells from day 11 EB cultures.
May-Grunwald-Giemsa stained hematopoietic cells in culture derived from c-fes/ ES cells (right panel), c-fes/c ES cells (center panel),
and c-fesc/c ES cells (left panel). (B) FACS analysis of lymphoid and myeloid cells in wild-type and c-fesc/c embryonic chimeras. Wild-type
and c-fesc/c ES cells were injected into C57BL/6 blastocysts to produce control and experimantal chimeras. The left panels depict the
wild-type chimera, and the right panels the c-fesc/c chimera. Ly9.1 staining detects ES cell-derived cells. Fetal liver B lymphoid and
myeloid cells were analyzed by using B220 (upper panels) and CD11b (middle panels), respectively. Fetal thymocytes were analyzed by
using CD4 (lower panels).
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FIG. 3. In vitro differentiation of c-fesc/c ES cells results in a hyperproliferation of an early myeloid cell. (A, B) In the in vitro
differentiation system, monocyte outgrowth is normally seen beginning on day 10 of differentiation. (A) A typical day 7 wild-type in vitro
differentiation culture showing three developing embryoid bodies. (B) A day 7 culture of the c-fesc/c ES cells. The mutant culture contains
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The primers were engineered to create XbaI sites at both ends of
the cDNA. Two TGA in frame stop codons were added to the 3 end
of the cDNA to ensure termination of translation.
A 50-l PCR was set up as follows: 0.5 l BioExact Polymerase
(Madison, WI), 5 l 10 BioExact OptiBuffer (No MgCl2), 2.5 l 50
mM MgCl2, 8 l of dNTPs (final of 0.4 M), 125 ng plasmid DNA
containing human c-fes cDNA (gift from Ricardo Feldman), and
100 ng of each primer. PCR cycles (30) were performed with the
following temperature profile: denaturation at 98°C for 20 s and
primer annealing and extension at 68°C for 5 min. The resulting
XbaI PCR fragment corresponding to human c-fes cDNA exons
1–10 was ligated into the c-fes locus control region (LCR) vector,
c-fesgh4.2. This vector results in copy number-dependent and
integration-independent transgene expression, under the control of
the c-fes promoter (Heydemann et al., 2000).
The resultant construct (hfesc) was linearized with HindIII, and
30 g of DNA was used to transform 2  107 c-fes/ ES cells
(Hackenmiller et al., 2000) along with 3 g of linearized PGK-
HYGRO as a selectable marker. After 8 days of selection in 0.2
mg/ml hygromycin containing media, antibiotic-resistant colonies
were picked and transferred into individual culture. Southern
analysis of the DNA of the colonies was performed following XbaI
digestion by using exons 1–10 of the human c-fes cDNA as the
probe. The clones with the highest copy number were selected for
further study.
RESULTS
Disruption of the mouse c-fes gene. A mutated c-fes
allele was produced by deleting a portion of the protein
coding region via gene targeting (see Materials and Meth-
ods). The targeting construct resulted in loss of 2.5 kb of
genomic DNA that contains three exons encoding amino
acids 497–607 (Fig. 1A). These amino acids correspond to
the C-terminal SH2 domain and ATP binding site within
the tyrosine kinase domain. Any protein product generated
from this targeted allele would lack both the SH2 domain
and kinase activity. Targeted ES cells were identified by
production of a novel 4.3-kb SphI restriction fragment
length polymorphism (RFLP) in addition to the wild-type
9.4-kb allele (Fig. 1B, lanes 2 and 3). ES cells homozygous for
the c-fes mutation were selected by growth in high concen-
trations of G418 (Mortensen et al., 1992). Reduction to
homozygosity was monitored by using the SphI RFLP
analysis for loss of the 9.4-kb wild-type fragment (Fig. 1B,
lane 4). To distinguish this allele from our c-fes null allele
(c-fes/) (Hackenmiller et al., 2000), it will be referred to as
c-fes/c for heterozygous cells and animals and c-fesc/c for
homozygous mutant cells and animals. Of note, neither
transcript nor protein levels of the upstream gene fur were
altered by the targeted disruption at the c-fes locus (data not
shown).
c-fes is not essential for erythroid, myeloid, or lymphoid
cell development. ES cells efficiently differentiate in vitro
into hematopoietic cells when cultured with appropriate
cytokines and gel matrix support (Keller et al., 1993). Under
specific culture conditions, embryoid bodies (EBs) produce
primitive erythrocytes, definitive erythrocytes, macro-
phages, neutrophils, and early megakaryocytes (Keller et al.,
1993). To determine whether erythrocytes and monocytes/
macrophages were being produced in c-fesc/c differentia-
tion cultures, cytospin preparations were performed on
c-fes/, c-fes/c, c-fesc/c EBs after 11 days of in vitro
differentiation. May-Grunwald-Giemsa stained erythro-
cytes, monocytes, and macrophages were readily detected
in slides prepared from c-fes/, c-fes/c, and c-fesc/c cul-
tures (Fig. 2A). Additionally, staining of these cells with
antibodies to the macrophage-specific markers CD11b and
F4/80 demonstrated the presence of CD11B and F4/80
macrophages in cultures from all three genotypes (data not
shown).
To determine whether c-fes was essential for hematopoi-
esis in vivo, c-fesc/c ES cells were used to generate chi-
meric embryos. Wild-type or c-fesc/c ES cells were injected
into C57BL/6 blastocysts to produce control and experi-
mental chimeras, respectively. We examined the ability of
c-fesc/c ES cells to generate lymphoid and myeloid cell
lineages in chimeric embryos using flow cytometry. ES
cell-derived lymphoid and myeloid progeny express the
Ly9.1 cell surface marker, thereby distinguishing them
from blastocyst-derived cells, which are Ly9.2. We deter-
mined that both c-fes/ and c-fesc/c ES cells contribute to
B lymphocytes (B220, Ly9.1) and myeloid cells (CD11b,
Ly9.1) in the fetal liver and T lymphocytes (CD4, Ly9.1)
in the fetal thymus (Fig. 2B). Therefore, based on May-
Grunwald-Giemsa staining and flow cytometry analysis of
ES cell contribution to lymphoid and myeloid lineages,
a large number of cells surrounding the developing embryoid bodies. (C, D) Representative cells from day 7 c-fesc/c EB cultures. When the
cells surrounding the c-fesc/c day EBs are isolated and stained with May-Grunwald-Giemsa, the morphology and staining pattern is
characteristic of an early myeloid cell. Cytospins are shown at 40 (C) and 64 (D). Arrow indicates monocyte. Bold arrow indicates
immature neutrophil. (E) Day 6 in vitro differentiated EBs were prepared from c-fes/, c-fes/c, c-fesc/c cultures and replated in
methylcellulose media identical to the original in vitro differentiation media. After 7 days of incubation, colonies were scored as CFU-E
(erythroid), CFU-M (macrophage), CFU-GM (granulocyte-macrophage), CFU-G (granulocyte), and CFU-GEMM (granulocyte-erythroid-
macrophage-megakaryocytes). Different colony types were scored by morphological and cytochemical data. The bar graph depicts the
number of CFU-M colonies as a percent of the total number of colonies to account for the difference in total colony number between
cultures. These numbers represent the average from three separate experiments. Asterisk denotes a significant difference (P  0.035) in the
number of CFU-M between c-fes/ and c-fesc/c cultures.
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intact Fes protein is not essential for the production of
erythrocytes, monocytes, macrophages, B cells, or T cells.
Hyperproliferation of myeloid cells in c-fesc/c differen-
tiation cultures. During in vitro differentiation, cells mi-
grating out from the compact embryoid body are first
observed on day 10 of culture. May-Grunwald-Giemsa and
monocyte-specific antibody staining have demonstrated
that these cells emanating from EBs are monocytes and
macrophages (Hackenmiller et al., 2000; and data not
shown). Surprisingly, when c-fesc/c cultures were exam-
ined on day 7, an excessive number of cells appeared to
surround the EBs (Fig. 3B). In contrast, wild-type day 7
cultures exhibited only compact EBs (Fig. 3A). On day 8,
c-fesc/c cultures were filled with such migratory cells,
while wild-type cultures still contained only compact EBs.
A similar hyperproliferation was demonstrated with five
independently derived c-fesc/c clones. Of note, c-fes/c
heterozygous clones appeared to have an intermediate hy-
perproliferation phenotype (data not shown).
Day 7 differentiated c-fesc/c cells were isolated and
stained for further characterization. Based on morphology
and staining characteristics, most of the cells appear to be
monoblasts and promonocytes, with a few immature mono-
cytes and neutrophils (Figs. 3C and 3D). During monocytic
differentiation, monoblasts are the first clearly recognizable
cell type. May-Grunwald-Giemsa-stained monoblasts are
characterized by deep blue cytoplasm and a large, dark
staining eccentric nucleus (Trinchieri, 1990). The progeny
of monoblasts are promonocytes. Promonocytes have light
blue cytoplasm, a slightly indented eccentric nucleus, and
an irregular cell margin. Promonocytes undergo two cell
divisions before maturation into monocytes. Monocytes
have gray–blue cytoplasm containing many granules and
vacuoles, and an indented, sometimes kidney-shaped
nucleus (see arrow, Figs. 3C and D). The indented nucleus
becomes more prominent as the monocyte matures. Neu-
trophils originate from the bi-potential CFU-GM (granulo-
cyte, monocyte) that also gives rise to monocytes. The most
prominent feature of a neutrophil is its lobulated nucleus.
In a mature neutrophil, there are usually five lobes con-
nected by fine strands of nuclear material, but in less
mature neutrophils, the nucleus usually exhibits two to
three lobes (Figs. 3C and 3D, bold arrows).
Monoblasts, promonocytes, and monocytes are motile
and phagocytic cells. Blunt pseudopods, present on almost
every cell in the c-fesc/c cytospins (Figs. 3C and 3D), are
the manifestation of motility and phagocytosis, suggesting
that the majority of such cells are of monocytic origin.
Antibody staining of the c-fesc/c cells for the monocytic
marker CD11b was negative (data not shown). If the major-
ity of the cells in the c-fesc/c culture were monoblasts and
promonocytes, they would express little of this marker
(Trinchieri, 1990).
To assess directly the effects of the c-fes mutation on
hematopoietic progenitor populations during in vitro differ-
entiation, in vitro colony-forming (clonogenic) assays were
performed. Single-cell suspensions of day 6 EBs were pre-
pared and then cultured for 7 days in methylcellulose
medium supplemented with growth factors that support
the proliferation and differentiation of erythroid and my-
eloid progenitors. Colony type (CFU) and number were
scored by microscopic examination. Colony identity was
confirmed by cytocentrifugation and May-Grunwald-
Giemsa staining. c-fes/, c-fes/c, and c-fesc/c cultures
contained an equivalent distribution of erythroid (CFU-E),
granulocyte-monocyte (CFU-GM), and granulocyte-
erythroid-megakaryoctye-macrophage (CFU-GEMM) pro-
genitors (data not shown). In contrast, c-fesc/c cultures
contained almost a twofold increase in the number of
macrophage (CFU-M) progenitors (Fig. 3E) as compared
with c-fes/ cultures. This increase was observed in three
separate experiments, with five independently derived
c-fesc/c clones. The increase in CFU-M progenitor num-
bers, together with the hyperliferation of monocytic cells
suggest that c-fes has a role in the negative regulation of the
growth and differentiation of myeloid cells.
Embryonic lethality of c-fes/c and c-fesc/c chimeras.
Undifferentiated heterozygous c-fes/c ES cells were in-
jected into normal mouse blastocysts to derive a c-fesc/c
strain. Upon injection of greater than 60 blastocysts im-
planted in 7 different pseudopregnant mothers, we obtained
no viable chimeric animals. Of note, three independently
derived c-fes/c clones were injected on multiple days.
Therefore, chimeric embryos were analyzed at different
stages of fetal development to determine why no viable
c-fes/c chimeric progeny were recovered. When embryos
were examined at days E15.5 and E16.5, highly chimeric
c-fes/c animals exhibited a variety of reproducible defects
(Fig. 4A). The most striking feature of c-fes/c chimeras was
their enlarged size as compared with wild-type littermates
(0% chimeras). As the percent chimerism (i.e., percent
tissue derived from c-fes/c ES cells) increased, so did the
weight of E15.5 and E16.5 embryos (data not shown). The
highly chimeric c-fes/c embryos also appeared swollen,
with distended abdomens (Fig. 4A). In addition to their large
and swollen appearance, the majority of c-fes/c chimeras
displayed severe systemic hemorrhaging, punctate lesions
throughout the embryo, and pools of blood in the abdomi-
nal cavity.
Histological sections of E15.5 c-fes/c chimeric embryos
revealed additional defects associated with a high percent of
c-fes/c -derived cells within developing animals (Figs.
4B–4D). First, the frontal lobe and first ventrical of the brain
appear enlarged in the highly chimeric c-fes/c embryos
(Figs. 4C and 4D). From these sections, the brain also
appeared mispositioned, as if pushed toward the cephalic
area. One will notice the downward angle of the nose and
mouth in both strong c-fes/c chimeras as compared with
the wild-type littermate control. As observed in intact
embryos, the abdominal cavity appears swollen and the
organs are not compact but surrounded by fluid. The 77%
c-fes/c chimera (Fig. 4D) also exhibits a hemorrhagic liver.
Finally, the most striking feature of these sections is the
appearance of the embryonic heart (Figs. 4E–G). The left
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FIG. 4. Day 15.5 c-fes/c chimeric embryos. (A) The embryos pictured are representative of what is seen at day 15.5 and day 16.5 of fetal
development. The percentages listed below the embryos are the percent chimerism as determined by Southern blot analysis. Many of the
strong chimeras have massive hemorrhaging, often in the abdomen, on the head and down the spinal region. In addition to the
hemorrhaging, the strong c-fes/c chimeras have distended abdomens and appear grossly swollen. These pleiotropic defects are more severe
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panel shows a normal, healthy heart from a E15.5 wild-type
embryo (0% c-fes/c chimera). The middle panel depicts a
heart from a 62% c-fes/c chimera which is significantly
enlarged with grossly dilated ventricles. The outer compact
layer of the myocardium is abnormally thin, although the
inner trabecular layer is relatively normal. This embryo
displayed ventricular septal defects upon analysis of adja-
cent slides. The right panel shows the heart from a 77%
chimera that had a dilated chamber and thinned myocar-
dium. Highly chimeric embryos also exhibit increased
amounts of extracellular matrix between endothelial net-
works and the myocardium and increased trabeculation
(Fig. 4G). The thinned myocardium and dilated ventricles
are consistent with embryonic heart failure and may ac-
count for the extensive peripheral edema observed.
Highly chimeric c-fes/c embryos die between E14.5 and
E17.5. Approximately 85–100% chimeras are already dead
and being resorbed by E15.5 and E16.5 (data not shown). It
was noted that all observed defects (increased weight, tissue
hemorrhage, enlarged brains, and abnormal hearts) increase
in severity as percent c-fes/c chimerism increases. These
conclusions are the result of analyzing 60 embryos, from
nearly 200 blastocyst injections, using ES cells derived from
3 independently derived c-fes/c ES cell clones. Impor-
tantly, wild-type ES cells obtained from the same electro-
poration, selected in G418, and expanded identically as
c-fes/c ES clones, were able to generate viable animals
with a high degree of chimerism.
To determine whether two mutated copies of c-fes within
a developing embryo result in additional defects, undiffer-
FIG. 5. Day 13.5 c-fesc/c chimeric embryos. c-fesc/c ES cell clones were microinjected into C57BL/6 donor blastocytes, which were
subsequently implanted into CD1 pseudopregnant females (Bradley et al., 1984). The age of the embryos was defined based on the day of
implantation being E2.5. When day 14.5–16.5 c-fesc/c chimeric embryos were analyzed, no viable high level chimeras were observed. The
day 13.5 c-fesc/c shown are representative of the types of abnormalities that were consistently seen at this stage of development. Similar
to the defects in the c-fes/c chimeras, the c-fesc/c chimeras show many areas of hemorrhaging. In addition, the vasculature in the strong
c-fesc/c chimeras appears to be unorganized.
as the percent chimerism increases. (B–D) H  E whole embryo sections of day 15.5 c-fes/c demonstrate the gross differences between (B)
wild-type embryos (0% chimera) and strong c-fes/c chimeras (C, D) (62 and 77%). The most striking feature is the difference in size; the
strong chimeras are much larger than their wild-type littermates. In addition to the size difference, the strong chimeras also have
abnormally large forebrains, abnormal hearts, and potentially abnormal livers (far top right panel). (E–G) Close-up of H  E sections
highlighting the heart defects. The bottom left panel shows a normal, healthy heart from a wild-type day 15.5 embryo. The bottom middle
panel is the heart from a 62% c-fes/c chimera. It is dilated and has very thin walls. The bottom right panel is the heart from a 77% c-fes/c
chimera. This heart is necrotic and most likely was nonfunctional. These heart defects could be contributing to the swollen appearance of
the strong chimeras (Figs. 3B–3D), possibly as a result of congestive heart failure.
263Truncation of c-fes Causes Embryonic Lethality
© 2002 Elsevier Science (USA). All rights reserved.
entiated homozygous c-fesc/c ES cells (three independent
clones) were injected into normal mouse blastocysts to
derive c-fesc/c chimeras. When E14.5–E16.5 c-fesc/c chi-
meric embryos were analyzed, no viable, high percentage
chimeras were recovered. Approximately 25% c-fesc/c chi-
meras were the highest chimeras obtained by E16.5. On day
E13.5, live c-fesc/c chimeras as high as 75% were identified
and analyzed (Fig. 5). Similar to defects noted in the highly
chimeric c-fes/c embryos, high c-fesc/c chimeras exhib-
ited multiple areas of hemorrhaging in particular in the
abdomen, with punctate lesions throughout the embryo. In
addition to hemorrhaging, many vessels in the c-fesc/c
chimeras appeared unorganized and disrupted (data not
shown), giving the embryos a blotchy red appearance
throughout the body. In contrast to the c-fes/c chimeric
embryos, the high c-fesc/c chimeras die between E12.5 and
E14.5, with no viable highly chimeric embryos observed on
E14.5.
Chimera analysis demonstrates that c-fes plays a critical
role in embryonic development. Even in c-fes/c chimeric
embryos, this mutation is lethal. The primary defect seems
to be in the circulatory system, with both heart and
vascular abnormalities observed in the c-fes/c and c-fesc/c
chimeras. Since c-fes is expressed in rapidly proliferating
tissues during development and in vascular endothelial
cells, perhaps c-fes is needed to regulate proliferation of
these tissues to allow for proper development and differen-
tiation. Similar to its proposed role in myeloid differentia-
tion, c-fes may also be involved in the regulation of growth
and differentiation during embryonic development.
Targeted disruption of the c-fes locus results in the
generation of an aberrant transcript and truncated Fes
protein. Difficulties encountered while attempting to
generate c-fes/c mice, and abnormal proliferation of
c-fesc/c myeloid cells prompted a detailed examination of
this targeted c-fes locus. The first indication of an aberrant
c-fes transcript came from Northern analysis of c-fesc/c ES
day 11 differentiation mRNA (data not shown). Using the
c-fes 3-UTR as a probe, several additional c-fes transcripts
were detected in the RNA samples obtained from c-fesc/c
cells. When a probe corresponding to c-fes exons 2–11 was
utilized, only wild-type and c-fes/c samples showed de-
tectable c-fes mRNA.
RT-PCR analysis of the c-fes locus using undifferentiated
ES cell RNA demonstrated that primers upstream (exons
8–10) and downstream (exons 16–18) of the deletion (exons
12–14) gave PCR products of the predicted size. Surpris-
ingly, primers spanning the deletion (exons 10–16) gener-
ated products of unexpected size (Fig. 6A). Wild-type RNA
(/ lane) shows the predicted PCR product of 774 bp for
exons 10–16, while both the c-fes/c and c-fesc/c RNAs
(/ and / lanes) show a product of 369 bp. A 477-bp
PCR product is expected with c-fesc/c RNA if the targeted
disruption resulted in the deletion of exons 12–14.
To determine the composition of aberrant c-fesc/c tran-
scripts, PCR products were subjected to DNA sequence
analysis. Sequence examination of five independently de-
rived c-fesc/c undifferentiated ES cell PCR samples estab-
lished that such transcripts contain c-fes cDNA exon 10,
101 bp of the PGK-neo poly(A) sequence from the neo
cassette in the targeting vector, an in frame stop codon, and
exons 15 and 16 of the c-fes cDNA (Fig. 6B). When this
sequence information is incorporated into the context of
the full-length c-fes mRNA, the resulting transcript con-
tains exons 1–10, a 101-bp portion of PGK-neo, an in frame
stop codon, and exons 15–19 (Fig. 6B). Deletion of exon 11
was confirmed by RT-PCR analysis using primers based in
exons 11 and 16, which resulted in no detectable product in
the c-fesc/c RNA samples (data not shown).
Translation of this aberrant c-fesc/c transcript would
generate a truncated Fes protein that retained the first 438
amino acids of the N-terminal region, but lacked the entire
C-terminal SH2 domain and tyrosine kinase domain (Fig.
6C). Interestingly, this N-terminal region of c-fes has re-
cently been shown to contain an oligomerization domain
which mediates the formation of Fes multimers (Read et al.,
1997). Oligomerization may be important for kinase activa-
tion and signaling in vivo (Cheng et al., 1999) and truncated
Fes could suppress the kinase activity of the wild-type
protein. We believe it is the presence of this truncated Fes
protein which leads to the large number of defects seen in
both the c-fesc/c myeloid cells and c-fes/c and c-fesc/c
chimeric animals.
Recapitulation of myeloid hyperproliferation with a
truncated human c-fes transgene. Day 7 in vitro differen-
tiated c-fesc/c ES cells produce a large number of myeloid
cells not detected in wild-type cultures (see Fig. 2). To
establish that this hyperproliferation phenotype is the re-
sult of expression of a truncated Fes protein, we constructed
a plasmid containing the human c-fes promoter, exons 1–10
of human c-fes cDNA, and the c-fes locus control region
(Fig. 7A) (Heydemann et al., 2000). Human c-fes exons 1–10
correspond to the predicted protein product generated in
c-fesc/c ES cells (Fig. 6C). Based on work from Heydemann
et al. (2000), this construct should express human c-fes
mRNA in a manner identical to the endogenous c-fes gene
when transfected into c-fes/ ES cells (c-fes/ ES cells
express no Fes protein) (Hackenmiller et al., 2000). Since
the c-fes/ ES cells are G418-resistant, a cDNA-encoding
resistance to the drug hygromyocin was coelectroporated
with the human truncated cDNA construct to select for
stable transformants.
Clones containing high copy numbers of intact transgene
were differentiated in vitro to determine whether introduc-
tion of a truncated human Fes protein would lead to a
hyperproliferative phenotype. After 7 days of in vitro differ-
entiation, cultures were assessed for the presence of my-
eloid outgrowth. As observed in c-fesc/c cultures at day 7 of
in vitro differentiation, day 7 cultures of c-fes/ ES cells
transfected with the truncated human transgene (c-fes/ 
hfesc) also exhibited large numbers of cells emanating
from EBs (Fig. 7B). Furthermore, cytospin analysis con-
firmed that these cells were very similar to those detected
in c-fesc/c cultures (data not shown). Importantly, in vitro
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differentiation of c-fes/ ES cells (Hackenmiller et al.,
2000) and stable transformants lacking an intact human
c-fes cDNA does not result in a hyperproliferative pheno-
type. These results suggest that myeloid hyperproliferation
is not due to inadvertent mutations introduced at the time
of the initial c-fes gene targeting, but are a direct result of
the presence of a truncated Fes protein. We conclude that
gene targeting resulted in a “gain-of-function” c-fes allele
that leads to uncontrolled myeloid cell growth and embry-
onic lethality.
DISCUSSION
c-fes encodes a 93-kDa tyrosine kinase highly expressed
in myeloid and vascular endothelial cells (Brach et al., 1991;
Emilia et al., 1986; Feldman et al., 1985; Ferrari et al., 1985;
Greer et al., 1994; Haigh et al., 1996). Previous reports
suggest that Fes is involved in myeloid cell growth and
differentiation (Nelson et al., 1998; Park et al., 1998;
Smithgall et al., 1988; Yates and Gasson, 1996; Yu et al.,
1988, 1989). To investigate the function of c-fes, ES cells
were generated with a targeted disruption at the c-fes locus
(c-fesc/c). Differentiation of c-fesc/c ES cells resulted in a
hyperproliferation of early myeloid cells. Generation of
c-fes/c and c-fesc/c chimeric mice demonstrated that this
mutation in c-fes is lethal, resulting in profound cardiac and
vascular defects in c-fes mutant embryos. Taken together,
these results establish that c-fes is important for the control
of myeloid cell growth and differentiation, as well as
embryonic cardiovascular development.
Extensive RT-PCR analysis of the targeted c-fes locus
determined that this mutation in c-fes deletes exons 11–14.
Translation of mutant c-fesc/c transcripts should result in
truncated Fes protein lacking the C-terminal SH2 and
tyrosine kinase domains, with the N-terminal oligomeriza-
tion domain intact (Fig. 6C). Expression of the correspond-
ing human c-fes amino acids in c-fes/ ES cells demon-
strated that the hyperproliferative phenotype of c-fesc/c ES
cells, and most likely the embryonic lethality, is due to the
presence of this truncated Fes protein. This mutant c-fes
allele likely results in a gain-of-function allele that inter-
feres with normal c-fes signal transduction and possibly
c-fer signaling pathways. Neither the myeloid hyperprolif-
eration nor the embryonic lethality are phenotypes seen in
the absence of the Fes protein (c-fes/) (Hackenmiller et al.,
2000), suggesting that the c-fesc/c phenotypes are the result
of a dominant Fes protein.
Fes was originally identified as the cellular component of
retroviral proteins that caused myeloid leukemia in cats
and chickens (Carmier and Samarut, 1986; Franchini et al.,
1981, 1982; Groffen et al., 1983; Hanafusa et al., 1980).
Although the underlying molecular cause of the c-fesc/c
hyperproliferation defect is not known, it is interesting that
this truncated Fes protein leads to the uncontrolled growth
of a myeloid cell.
GM-CSF is a hematopoietic cytokine important for my-
eloid cell growth, differentiation, and activation. Several
studies have shown that both c-fes and the Jak-Stat pathway
protein Stat3 become activated in response to GM-CSF
receptor engagement (Brizzi et al., 1996; Hanazono et al.,
1993; Linnekin et al., 1995). There is compelling evidence
FIG. 6. RT-PCR analysis of c-fesc/c mRNA reveals the produc-
tion of a truncated c-fes transcript. (A) RNA harvested from
undifferentiated ES cells was analyzed by RT-PCR using primers
that spanned the targeted portion of the c-fes gene (E10–16). The
wild-type lane (/) shows the predicted band of 774 bp. Two
separate / lanes show two transcripts; one of the predicted size
and one aberrant transcript. Only the aberrant transcript is seen in
the two / lanes. The J774 lane is a positive control for wild-type
c-fes transcript. The final lane of each gel (RT) shows a negative
control reaction containing wild-type day 11 in vitro differentiation
RNA with no reverse transcriptase (RT). /, c-fes/; /,
c-fes/c; and /, c-fesc/c. (B) Predicted transcript from c-fesc/c
locus. Sequencing of the aberrant PCR product identified the
transcript as exon 10, part of the PGK poly(A) signal from the neo
selectable marker and exons 15 and 16. The predicted full-length
mutant transcript would contain c-fes exons 1–10, a portion of the
PGK poly(A), an in frame stop codon, and exons 15–19 of c-fes. (C)
The top diagram depicts the wild-type Fes, illustrating the known
domains of the protein. The bottom diagram depicts the predicted
protein product from the translation of the aberrant c-fesc/c
transcript. The truncated c-fesc/c lacks the tyrosine kinase and
SH2 domains of the Fes protein. The N-terminal oligomerization
domain is retained in the truncated protein.
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to suggest that the two proteins associate in response to
GM-CSF signaling (Brizzi et al., 1996; Nelson et al., 1998;
Park et al., 1998). Stat3 is involved in many cytokine
signaling pathways (Garcia and Jove, 1998), but it is particu-
larly intriguing that improper Stat3 activation has been
shown to lead to transformation of fibroblasts, lympho-
cytes, and myeloid cells (Garcia and Jove, 1998). Addition-
ally, both Stat3 and Stat5 have been linked to cell cycle
control (Fukada et al., 1996, 1998; Matsumura et al., 1997),
suggesting that dysregulation of the Stats can result in
improper cell cycle progression. Perhaps both oncogenic
v-fes and truncated c-fesc/c result in inappropriate Stat3
signaling through the GM-CSF receptor, resulting in uncon-
trolled myeloid cell growth.
While the embryonic lethality of the c-fes/c and c-fesc/c
chimeric mice was unexpected, it has been shown that c-fes
is broadly expressed in the developing embryo and therefore
could play a role in embryogenesis. Several activated alleles
of c-fes have also uncovered unexpected roles for c-fes in
nonhematopoietic cell and tissue development. Expression
of v-fps regulated by the -globin promoter in transgenic
mice leads to the development of lymphoid and mesenchy-
mal tumors (Yee et al., 1989a), cardiovascular abnormalities
such as enlarged vessels and hearts and neurological defects
(Yee et al., 1989b). Furthermore, homozygous transgenic
lines expressing high levels of v-fps could not be generated
and many high copy number hemizygous transgenic mice
died within a week of birth from unknown causes (Yee et
al., 1989a,b). Greer et al. (1994) demonstrated that a my-
ristylated Fes protein expressed in transgenic mice results
in internal hemorrhaging and hypervascularity progressing
to multifocal hemangiomas. These authors also had diffi-
FIG. 7. Recapitulation of the myeloid hyperproliferation in c-fes/ ES cells. (A) Design of the human c-fes truncated protein vector
(hfesc). Exons 1–10 of the human c-fes cDNA were placed downstream of the 500-bp c-fes promoter and upstream of c-fes human genomic
exons 1–5 (LCR). Exons 4 and 5 of the human growth (GH) gene provide a splicing signal and polyadenylation site. (B) The HindIII linearized
vector was stably transfected into c-fes/ ES cells (Hackenmiller et al., 2000) to generate the c-fes/  hfesc cell line. The left panel
depicts a typical day 7 wild-type in vitro differentiation culture showing three embryoid bodies. The middle panel is a c-fesc/c day 7 culture,
which contains a large number of cells surrounding the developing embryoid bodies. The right panel is a c-fes/  hfesc day 7 culture,
showing similar outgrowth to the c-fesc/c day 7 culture. The c-fes/ cells without the hfesc transgene do not display any
hyperproliferation in this system.
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culty generating stable transgenic lines, with many of the
founders dying as neonates and all of the transgenic lines
dying by 7 months of age. Interestingly, the authors also
report that the in vitro proliferation potential of myeloid
progenitors is increased. Although these studies utilized an
activated c-fes allele, the similarities between these trans-
genic phenotypes and the c-fes/c and c-fesc/c chimeric
mice are striking. As suggested for the hyperproliferative
defect of the c-fesc/c ES cells, perhaps the phenotypes of
the c-fes/c and c-fesc/c chimeric embryos and the acti-
vated Fes transgenic mice are the result of similar dysregu-
lation of critical developmental signal transduction path-
ways.
The c-fesc/c allele is the third mutation of c-fes to be
reported. The first reported allele of c-fes (fpsK588R) is a point
mutation in the kinase domain that results in Fes having
reduced or no kinase activity (Senis et al., 1999). The
reported abnormalities of fpsK588R mice are subtle: slightly
elevated total leukocyte counts and splenomegaly. In addi-
tion, fpsK588R bone marrow-derived macrophages show re-
duced tyrosine phosphorylation of Stat3 and Stat5A in
response to GM-CSF. In contrast to the mild phenotype of
fpsK588R mice, c-fes/ mice (Hackenmiller et al., 2000)
exhibit homeostasis defects in B cells, macrophages, and
neutrophils, compromised innate immunity, and increased
activation of Stat3 and Stat5 in response to IL-6 and
GM-CSF. These results demonstrate that Fes regulates Stat
activation during cytokine-mediated signal transduction.
This c-fesc/c allele supports the hypothesis that Fes kinase
activity is not the most important function of the protein.
There are many potential explanations for how this
c-fesc/c allele could lead to dysfunctional development.
First, these phenotypes could result from a change in the
cellular distribution of Fes. Fes has been shown to reside in
the trans-Golgi network of the cytoplasm (Haigh et al.,
1996), and to be associated with cytokine receptors at the
cell membrane (Brizzi et al., 1996; Nelson et al., 1998; Park
et al., 1998). Perhaps deletion of the C terminus disrupts its
normal subcellular distribution. While this explanation is
feasible, the regulation and importance of the cellular
location of Fes are not understood, making this scenario
difficult to validate. A second explanation for the action of
the c-fesc/c allele could be the loss of a negative regulatory
domain resulting in an inappropriately active Fes. This
seems unlikely for several reasons. First, while negative
regulatory domains are known to be important for src-
family kinase regulation, no negative regulatory domain
has been identified for c-fes (Wilks and Kurban, 1988).
Second, this activated Fes protein would have to be exerting
its affects in the absence of the kinase domain, which is
deleted in the c-fesc/c allele.
The explanation we favor is that the truncated allele of
c-fes can still bind to many Fes substrates, but without the
kinase activity these substrates are not phosphorylated and
released by Fes to continue the signaling cascade. Instead,
Fes substrates are sequestered by the N-terminal truncated
protein. It has been shown that, in addition to mediating
the formation of Fes multimers (Read et al., 1997), the
N-terminal region is also important for the binding of Fes
substrates such as BCR (Maru et al., 1995). In addition, Fes
substrate sequestration may also prevent other proteins,
such as the highly related kinase Fer, from binding shared
substrates and compensate for the loss of Fes kinase activ-
ity. A final explanation is the possibility that in addition to
interfering with c-fes-mediated signaling, the c-fesc/c allele
is also disrupting c-fer signaling. The N-terminal region of
Fer also contains a coiled-coil domain which mediates the
formation of Fer multimers (Kim and Wong, 1995). It is
possible that the c-fes and c-fer N-terminal domains can
interact, although recent data show that heterotypic inter-
actions do not occur in transfected, overexpressing cell
lines (Craig et al., 1999). Perhaps in a certain developmental
context, Fes and Fer do interact and in this situation the
truncated Fes protein could be “poisoning” the Fer multim-
ers, crippling the activity of the resulting Fer–Fes protein
complex. While there is no direct evidence for a Fes/Fer
interaction, it is interesting that both regions contain
N-terminal oligomerization domains. It has also been dem-
onstrated that N-terminal Fer antibodies can detect Fes
protein, showing that the two regions of Fes and Fer are
antigentically cross-reactive (Pawson et al., 1989).
This study clearly establishes that c-fes is important for
both myeloid differentiation and embryonic development.
In addition, these results demonstrate that the N-terminal
region of c-fes is a critical component of c-fes signaling
pathways. Surprisingly, the conclusions drawn from these
experiments suggest that c-fes and the related kinase c-fer
have both unique and overlapping roles in intracellular
signaling pathways.
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